This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to investigate the safety and tolerability of NNC0114-0006 in subjects with systemic lupus erythematosus (SLE) concomitantly treated with stable background therapies.
Inclusion Criteria: * Men and women (not pregnant and not nursing) * Subjects with SLE meeting the American College of Rheumatology (ACR) criteria, with a disease duration of at least 6 months * Subjects with clinically active SLE defined as a Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score of at least 6 and positive for antinuclear antibody (ANA) and/or Anti-double-stranded DNA antibody (anti-dsDNA) * If taken, background medication must be stable Exclusion Criteria: * Presence or history of active lupus nephritis (LN) within the last 4 months or active central nervous system (CNS) disease within the last 12 months * Body mass index (BMI) below 18 kg/m\^2 or above 38 kg/m\^2
No linked publications found in PubMed